
CDTRP 2025 Research Innovation Grant Competition Results
CDTRP is thrilled to announce the results of the CDTRP 2025 Research Innovation Grant Competition, made possible through our partnership with various esteemed organizations. We are proud to showcase all of the exciting projects that have been funded in this year’s competition.
We would like to extend our warmest congratulations to Dr. Zhu-Xu Zhang and his team for being awarded the CDTRP LHSC Research Innovation Grant. We wish them all the best as they embark on their innovative project!
The Multi-Organ Transplant Program at London Health Sciences Centre has a long and proud history of supporting innovation and research, which directly contributes to improved care and quality of life for our patients. We are especially proud of Dr. Zhu-Xu Zhang, who research project “The Potential of Inhibiting Multiple Cell Death Pathways in Transplantation” holds promise of significantly enhancing transplant success and patient outcomes.
CDTRP LHSC Research Innovation Grant : Dr. Zhu-Xu Zhang
Project Title: The potential of inhibiting multiple cell death pathways in transplantation
Main affiliation: London Health Sciences Centre Research Institute
Theme: 3 – Engineer and Allocate Better Grafts
Lay Abstract
When a heart is irreversibly damaged and cannot be treated by any other medical or surgical means, organ transplantation is the most beneficial and highly pursued treatment option for saving the person’s life. However, the immune system of the graft recipient usually recognizes the transplant as a ‘stranger’, leading to organ rejection. Additionally, organ donor shortage is a devastating challenge in transplantation. 80% of transplants use deceased donor organs, and 20% use living donor organs. Unfortunately, most deceased donor organs are discarded because of extended injury, while 40% of patients on the organ waiting list have died. Novel therapeutic strategies are urgently required to preserve heart function and improve clinical outcomes.
Inflammation post-transplantation induces different “”forms”” of cell death and, subsequently, organ failure. We have revealed that multi-cell death pathways are activated simultaneously in the graft post-transplantation and contribute to acute and chronic transplant damage. However, these multi-cell death pathways are not affected by current anti-rejection drugs. We have recently found a strategy to block cell death and attenuate acute graft injury in mouse heart transplantation. In this grant, we will explore if targeting cell death molecular components offers a potential for therapeutic development to reduce short- and long-term damage in heart transplantation. Furthermore, we will identify molecules that control multiple cell death pathways in patient samples. Thus, these studies will guide future clinical therapies for inflammation and may lead to truly novel approaches for preventing transplanted heart graft injury and rejection in patients.